JP2012514021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514021A5 JP2012514021A5 JP2011544019A JP2011544019A JP2012514021A5 JP 2012514021 A5 JP2012514021 A5 JP 2012514021A5 JP 2011544019 A JP2011544019 A JP 2011544019A JP 2011544019 A JP2011544019 A JP 2011544019A JP 2012514021 A5 JP2012514021 A5 JP 2012514021A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligonucleotide
- composition according
- adjusted
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14184808P | 2008-12-31 | 2008-12-31 | |
| US61/141,848 | 2008-12-31 | ||
| PCT/EP2009/067561 WO2010076248A1 (en) | 2008-12-31 | 2009-12-18 | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012514021A JP2012514021A (ja) | 2012-06-21 |
| JP2012514021A5 true JP2012514021A5 (https=) | 2013-02-14 |
| JP5793423B2 JP5793423B2 (ja) | 2015-10-14 |
Family
ID=41698255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011544019A Expired - Fee Related JP5793423B2 (ja) | 2008-12-31 | 2009-12-18 | 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9132147B2 (https=) |
| EP (1) | EP2384197B1 (https=) |
| JP (1) | JP5793423B2 (https=) |
| ES (1) | ES2572361T3 (https=) |
| WO (1) | WO2010076248A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5793423B2 (ja) | 2008-12-31 | 2015-10-14 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用 |
| EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| WO2013173652A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| US20160138014A1 (en) | 2012-10-12 | 2016-05-19 | Isis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| US10077443B2 (en) * | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| CN104955952A (zh) * | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna寡核苷酸碳水化合物缀合物 |
| CN105164261B (zh) | 2013-05-01 | 2022-03-18 | 莱古路斯治疗法股份有限公司 | 用于增强的细胞摄取的化合物和方法 |
| SG11201508925WA (en) | 2013-05-01 | 2015-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| JP6519842B2 (ja) * | 2013-10-04 | 2019-05-29 | 国立大学法人神戸大学 | 福山型筋ジストロフィー治療用アンチセンス核酸 |
| KR20160083876A (ko) * | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| WO2016033424A1 (en) * | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| CA2966044A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
| EP3790972A1 (en) | 2018-05-08 | 2021-03-17 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7528118B2 (en) | 2004-09-24 | 2009-05-05 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of ApoB and uses thereof |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| AU2006291836B2 (en) * | 2005-09-15 | 2012-02-23 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-Bl00 expression |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| WO2007107162A2 (en) * | 2006-03-23 | 2007-09-27 | Santaris Pharma A/S | Small internally segmented interfering rna |
| CA2648132C (en) | 2006-04-03 | 2019-05-28 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| CA2681406A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2623599B1 (en) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| WO2009114475A2 (en) * | 2008-03-09 | 2009-09-17 | Intradigm Corporation | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use |
| AU2009238175C1 (en) * | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| JP5793423B2 (ja) | 2008-12-31 | 2015-10-14 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用 |
-
2009
- 2009-12-18 JP JP2011544019A patent/JP5793423B2/ja not_active Expired - Fee Related
- 2009-12-18 ES ES09795436T patent/ES2572361T3/es active Active
- 2009-12-18 EP EP09795436.6A patent/EP2384197B1/en not_active Not-in-force
- 2009-12-18 US US13/142,929 patent/US9132147B2/en not_active Expired - Fee Related
- 2009-12-18 WO PCT/EP2009/067561 patent/WO2010076248A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012514021A5 (https=) | ||
| WO2014022739A3 (en) | Modified rnai agents | |
| WO2013074974A3 (en) | Modified rnai agents | |
| BRPI1011229A2 (pt) | co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente. | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| CY1119140T1 (el) | Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους | |
| MX2016007409A (es) | Composiciones de acido ribonucleico de interferencia (ari) contra el componente del complemento y metodos para su uso. | |
| JP2013522184A5 (https=) | ||
| NZ597071A (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| MY162339A (en) | Nanoparticles loaded with chemotherapeutic antitumoral drug | |
| MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
| JP2012193216A5 (https=) | ||
| BR112013033309A2 (pt) | método para tratar ou prevenir pelo menos uma afecção inflamatória em um paciente, método para inibir lesões hepáticas em um paciente em risco de lesões hepáticas químicas provenientes de drogas prescritas ou drogas de abuso, método para inibir danos de tecido mediados por célula nkt tipo i em um paciente, método para inibir a ativação de células nkt tipo i, método para inibir a ativação de células nkt tipo i em um paciente com uma doença inflamatória e método para inibir a liberação de células mieloides no fígado de um paciente | |
| MX2011011656A (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
| BRPI0912842A8 (pt) | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| CL2013003497A1 (es) | Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. | |
| JP2016515586A5 (https=) | ||
| BR112015011778A2 (pt) | métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
| JP2015527316A5 (https=) | ||
| Radigan et al. | D97 ICU ACQUIRED MUSCLE WEAKNESS: MECHANISMS, DIAGNOSIS, AND TREATMENT: Targeting Muscle Degradation With Leptin | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis |